Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rodrigo A Toledo

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2024
Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working GroupAlexander W Wyatt, Saskia Litiere, Francois-Clément Bidard, et al.
Endocrine-Related Cancer|February 18, 2014
p27 variant and corticotropinoma susceptibility: a genetic and in vitro studyTomoko Sekiya, Marcello D Bronstein, Katiuscia Benfini, et al.
Nature Medicine|September 13, 2022
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF<sup>V600E</sup> metastatic colorectal cancerElena Elez, Javier Ros, Jose Fernández, et al.
The Journal of Clinical Endocrinology and Metabolism|December 25, 2012
Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RASNishant Agrawal, Yuchen Jiao, Mark Sausen, et al.
JAMA|December 16, 2010
Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomasLi Yao, Francesca Schiavi, Alberto Cascon, et al.
European Journal of Endocrinology|June 13, 2014
Association between the p27 rs2066827 variant and tumor multiplicity in patients harboring MEN1 germline mutationsViviane C Longuini, Delmar M Lourenço, Tomoko Sekiya, et al.
Endocrine-Related Cancer|June 27, 2017
The penetrance of MEN2 pheochromocytoma is not only determined by <i>RET</i> mutationsFrederic Castinetti, Ana Luiza Maia, Mariola Peczkowska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2025
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with ImmunotherapyElena Garralda, Charles Abbott, Alma Calahorro, et al.
Human Mutation|October 28, 2010
Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10Karin Frank-Raue, Lisa A Rybicki, Zoran Erlic, et al.
The Lancet. Oncology|April 22, 2014
Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based studyFrederic Castinetti, Xiao-Ping Qi, Martin K Walz, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2024
Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working GroupAlexander W Wyatt, Saskia Litiere, Francois-Clément Bidard, et al.
Endocrine-Related Cancer|February 18, 2014
p27 variant and corticotropinoma susceptibility: a genetic and in vitro studyTomoko Sekiya, Marcello D Bronstein, Katiuscia Benfini, et al.
Nature Medicine|September 13, 2022
RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAF<sup>V600E</sup> metastatic colorectal cancerElena Elez, Javier Ros, Jose Fernández, et al.
The Journal of Clinical Endocrinology and Metabolism|December 25, 2012
Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RASNishant Agrawal, Yuchen Jiao, Mark Sausen, et al.
JAMA|December 16, 2010
Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomasLi Yao, Francesca Schiavi, Alberto Cascon, et al.
European Journal of Endocrinology|June 13, 2014
Association between the p27 rs2066827 variant and tumor multiplicity in patients harboring MEN1 germline mutationsViviane C Longuini, Delmar M Lourenço, Tomoko Sekiya, et al.
Endocrine-Related Cancer|June 27, 2017
The penetrance of MEN2 pheochromocytoma is not only determined by <i>RET</i> mutationsFrederic Castinetti, Ana Luiza Maia, Mariola Peczkowska, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 16, 2025
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with ImmunotherapyElena Garralda, Charles Abbott, Alma Calahorro, et al.
Human Mutation|October 28, 2010
Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10Karin Frank-Raue, Lisa A Rybicki, Zoran Erlic, et al.
The Lancet. Oncology|April 22, 2014
Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based studyFrederic Castinetti, Xiao-Ping Qi, Martin K Walz, et al.
Pageof 7